Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection

Science Translational Medicine

Volumn 3, Issue 83, 2011, Pages

  Feng, Gang ^a   Nadig, Satish N ^a   Bäckdahl, Liselotte ^b   Beck, Stephan ^c   Francis, Ross S ^a   Schiopu, Alexandru ^a   Whatcott, Andrew ^a   Wood, Kathryn J ^a   Bushell, Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAMIDE; GAMMA INTERFERON; PHOSPHODIESTERASE III; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; QUINOLONE DERIVATIVE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG ACTIVITY; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN TRANSPLANTATION; VASCULAR DISEASE; ANIMAL; CYTOLOGY; DRUG EFFECT; GENETICS; METHYLATION;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; METHYLATION; MICE; QUINOLONES; T-LYMPHOCYTES, REGULATORY;

EID: 79956272192     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002099     Document Type: Article

References (51)

1. C. L. Bennett, J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, H. D. Ochs, The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20-21 (2001).
2. R. S. Wildin, F. Ramsdell, J. Peake, F. Faravelli, J. L. Casanova, N. Buist, E. Levy-Lahad, M. Mazzella, O. Goulet, L. Perroni, F. D. Bricarelli, G. Byrne, M. McEuen, S. Proll, M. Appleby, M. E. Brunkow, X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27, 18-20 (2001).
3. S. Hori, T. Nomura, S. Sakaguchi, Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
4. L. M. Williams, A. Y. Rudensky, Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8, 277-284 (2007).
5. + regulatory T cells induces a scurfy-like disease. J. Exp. Med. 204, 57-63 (2007).
6. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002).
7. - precursors. J. Immunol. 169, 4183-4189 (2002).
8. high regulatory T cells. Blood 104, 895-903 (2004).
9. + regulatory T cells. Eur. J. Immunol. 38, 2512-2527 (2008).
10. + regulatory T cells that prevent allograft rejection: Potential avenues for cellular therapy. Transplantation 86, 578-589 (2008).
11. M. Conti, J. Beavo, Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511 (2007).
12. G. M. Kammer, The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9, 222-229 (1988).
13. R. Mandler, R. E. Birch, S. H. Polmar, G. M. Kammer, S. A. Rudolph, Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. U.S.A. 79, 7542-7546 (1982).
14. D. Mary, C. Aussel, B. Ferrua, M. Fehlmann, Regulation of interleukin 2 synthesis by cAMP in human T cells. J. Immunol. 139, 1179-1184 (1987).
15. A. Shore, H. Dosch, E. W. Gelfand, Induction and separation of antigen-dependent T helper and T suppressor cells in man. Nature 274, 586-587 (1978).
16. N. E. Goeken, J. S. Thompson, Suppressor cells induced in the human autologous mixed lymphocyte reaction. Hum. Immunol. 4, 37-45 (1982).
17. Y. Zheng, A. Y. Rudensky, Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8, 457-462 (2007).
18. J. A. Hill, M. Feuerer, K. Tash, S. Haxhinasto, J. Perez, R. Melamed, D. Mathis, C. Benoist, Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27, 786-800 (2007).
19. M. A. Gavin, J. P. Rasmussen, J. D. Fontenot, V. Vasta, V. C. Manganiello, J. A. Beavo, A. Y. Rudensky, Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445, 771-775 (2007).
20. J. J. Kobie, P. R. Shah, L. Yang, J. A. Rebhahn, D. J. Fowell, T. R. Mosmann, T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J. Immunol. 177, 6780-6786 (2006).
21. S. Deaglio, K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, V. K. Kuchroo, T. B. Strom, S. C. Robson, Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
22. - T cells via p53, IL-2, and OX40. Proc. Natl. Acad. Sci. U.S.A. 104, 15478-15483 (2007).
23. F. Murad, Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N. Engl. J. Med. 355, 2003-2011 (2006).
24. E. Degerman, P. Belfrage, V. C. Manganiello, Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem. 272, 6823-6826 (1997).
25. A. T. Bender, J. A. Beavo, Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol. Rev. 58, 488-520 (2006).
26. S. Floess, J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H. D. Chang, T. Bopp, E. Schmitt, S. Klein-Hessling, E. Serfling, A. Hamann, J. Huehn, Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5, e38 (2007).
27. R. S. Francis, G. Feng, T. Tha-In, I. S. Lyons, K. J. Wood, A. Bushell, Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur. J. Immunol. 41, 726-738 (2011).
28. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
29. + cells in the recipient. Int. Immunol. 18, 279-289 (2006).
30. M. Carvalho-Gaspar, N. D. Jones, S. Luo, L. Martin, M. O. Brook, K. J. Wood, Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J. Immunol. 180, 6640-6648 (2008).
31. J. M. Kim, J. P. Rasmussen, A. Y. Rudensky, Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191-197 (2007).
32. L. Chatenoud, CD3-specific antibody-induced active tolerance: From bench to bedside. Nat. Rev. Immunol. 3, 123-132 (2003).
33. + regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am. J. Transplant. 8, 793-802 (2008).
34. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9, 1144-1150 (2003).
35. S. N. Nadig, J. Wieckiewicz, D. C. Wu, G. Warnecke, W. Zhang, S. Luo, A. Schiopu, D. P. Taggart, K. J. Wood, In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat. Med. 16, 809-813 (2010).
36. - T regulatory cells. Clin. Immunol. 133, 22-26 (2009).
37. C. G. Brunstein, J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. DeFor, B. L. Levine, C. H. June, P. Rubinstein, P. B. McGlave, B. R. Blazar, J. E.Wagner, Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117, 1061-1070 (2011).
38. F. Lühder, J. Katz, C. Benoist, D. Mathis, Major histocompatibility complex class II molecules can protect from diabetes by positively selecting T cells with additional specificities. J. Exp. Med. 187, 379-387 (1998).
39. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162, 5317-5326 (1999).
40. S. Sakaguchi, T. Yamaguchi, T. Nomura, M. Ono, Regulatory T cells and immune tolerance. Cell 133, 775-787 (2008).
41. + regulatory T cells without enhancing effector T-cell function. Am. J. Transplant. 7, 759-768 (2007).
42. R. J. Benjamin, H. Waldmann, Induction of tolerance by monoclonal antibody therapy. Nature 320, 449-451 (1986).
43. +CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: Antigen-specific reactivation in vivo is critical for bystander regulation. Blood 105, 4871-4877 (2005).
44. + regulatory T cells via a TGF-β- and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757-1764 (2007).
45. S. Qin, S. P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, H. Waldmann, "Infectious" transplantation tolerance. Science 259, 974-977 (1993).
46. T. Bopp, C. Becker, M. Klein, S. Klein-Hessling, A. Palmetshofer, E. Serfling, V. Heib, M. Becker, J. Kubach, S. Schmitt, S. Stoll, H. Schild, M. S. Staege, M. Stassen, H. Jonuleit, E. Schmitt, Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204, 1303-1310 (2007).
47. L. Li, C. Yee, J. A. Beavo, CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283, 848-851 (1999).
48. A. Nakata, K. Ogawa, T. Sasaki, N. Koyama, K. Wada, J. Kotera, H. Kikkawa, K. Omori, O. Kaminuma, Potential role of phosphodiesterase 7 in human T cell function: Comparative effects of two phosphodiesterase inhibitors. Clin. Exp. Immunol. 128, 460-466 (2002).
49. J. Tost, I. G. Gut, DNA methylation analysis by pyrosequencing. Nat. Protoc. 2, 2265-2275 (2007).
50. J. L. Royo, M. Hidalgo, A. Ruiz, Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping. Nat. Protoc. 2, 1734-1739 (2007).
51. -/-mice; H. Waldman for providing hCD25 transgenic mice; the staff of the Biomedical Service Unit, John Radcliffe Hospital, for animal care; N. Jones for advice and discussion of the data obtained using BM3 TCR transgenic mice; and J. Huehn for critical appraisal of the manuscript. Funding: This work was supported by The Wellcome Trust, the European Union Framework 6 Integrated Project, RISET, and the British Heart Foundation (PG/06/050). G.F. received a Dorothy Hodgkin Post-Graduate Award and support from the China-Oxford Scholarship Fund. R.S.F. received a Kidney Research UK Training Fellowship. S.N.N. received an American Society of Transplantation Research Fellowship Award. S.B. was funded by the Wellcome Trust (084071) and a Royal Society Wolfson Research Merit Award. A.S. is supported by the Swedish Heart and Lung Foundation and the Swedish Research Council. K.J.W. holds a Royal Society Wolfson Research Merit Award. Author contributions: G.F. designed and conducted the experiments, analyzed the data, and contributed original ideas. R.S.F. designed and conducted key in vivo experiments. S.N.N. and A.S. performed and analyzed the human arterial transplants. K.J.W. obtained funding and provided important ideas, comments, and leadership. A.W. performed key repeat experiments. S.B. and L.B. designed and performed the bisulfite sequencing experiments and interpreted the data. A.B. designed the experiments, interpreted the data, and wrote the manuscript. Competing interests: The authors declare that they have no competing interests.